Objectives: The aim of this study was to screen lone atrial fibrillation (AF) patients for mutations in the genes KCNJ2, KCNJ3 and KCNJ5, all encoding potassium channels. Furthermore, we wanted to replicate the prior association of two single-nucleotide polymorphisms (SNPs) in KCNJ5, C171T (rs6590357) and G810T (rs7118824), with lone AF in Han Chinese. Methods: We sequenced the coding region and splice site of KCNJ2, KCNJ3 and KCNJ5 in 187 early-onset lone-AF patients screening for mutations and counting SNP frequencies for the two noted SNPs in KCNJ5. Results: No mutations were found in KCNJ2, KCNJ3 or KCNJ5. Both genotype distribution and allele frequencies of the SNPs rs6590357 and rs7118824 significantly differed between the AF and control group (pgenotype = 0.0067, pallele = 0.0021 and pgenotype = 0.014, pallele = 0.0101, respectively). On allele level, the OR for lone AF for rs6590357 was 1.77 (95% CI 1.16–2.73, p = 0.009) and for rs7118824 it was 1.71 (95% CI 1.13–2.57, p = 0.01) in a model adjusted for age and gender. Conclusions: Our findings indicate that rs6590357 and rs7118824 in KCNJ5 are associated with early-onset lone AF in Caucasians. No mutations were found in the exon or splice site of KCNJ2, KCNJ3 or KCNJ5.

Keywords:
Genetic, Genetics, Lone atrial fibrillation, Single-nucleotide polymorphism, KCNJ2, KCNJ3, KCNJ5, GIRK4
1.
Lloyd-Jones DM, Wang TJ, Leip EP, Larson MG, Levy D, Vasan RS, et al: Lifetime risk for development of atrial fibrillation: the Framingham Heart Study. Circulation. 2004;110:1042–1046.
2.
Heeringa J, van der Kuip DAM, Hofman A, Kors JA, van Herpen G, Stricker BHC, et al: Prevalence, incidence and lifetime risk of atrial fibrillation: the Rotterdam study. Eur Heart J 2006;27:949–953.
3.
Fox CS, Parise H, D’Agostino RB, Lloyd-Jones DM, Vasan RS, Wang TJ, et al: Parental atrial fibrillation as a risk factor for atrial fibrillation in offspring. JAMA. 2004;291:2851–2855.
4.
Andalib A, Brugada R, Nattel S: Atrial fibrillation: evidence for genetically determined disease. Curr Opin Cardiol 2008;23:176–183.
5.
Arnar DO, Thorvaldsson S, Manolio TA, Thorgeirsson G, Kristjansson K, Hakonarson H, et al: Familial aggregation of atrial fibrillation in Iceland. Eur Heart J 2006;27:708–712.
6.
Christophersen IE, Ravn LS, Budtz-Joergensen E, Skytthe A, Haunsoe S, Svendsen JH, et al: Familial aggregation of atrial fibrillation: a study in Danish twins. Circ Arrhythmia Electrophysiol 2009;2:378–383.
7.
Wakimoto H, Maguire CT, Kovoor P, Hammer PE, Gehrmann J, Triedman JK, et al: Induction of atrial tachycardia and fibrillation in the mouse heart. Cardiovasc Res 2001;50:463–473.
8.
Kovoor P, Wickman K, Maguire CT, Pu W, Gehrmann J, Berul CI, et al: Evaluation of the role of IKACh in atrial fibrillation using a mouse knockout model. J Am. Coll Cardiol 2001;37:2136–2143.
9.
Schauerte P, Scherlag BJ, Pitha J, Scherlag MA, Reynolds D, Lazzara R, et al: Catheter ablation of cardiac autonomic nerves for prevention of vagal atrial fibrillation. Circulation 2000;102:2774–2780.
10.
Lemola K, Chartier D, Yeh Y, Dubuc M, Cartier R, Armour A, et al: Pulmonary vein region ablation in experimental vagal atrial fibrillation: role of pulmonary veins versus autonomic ganglia. Circulation 2008;117:470–477.
11.
Yamada M, Inanobe A, Kurachi Y: G protein regulation of potassium ion channels. Pharmacol Rev 1998;50:723–760.
12.
Corey S, Clapham DE: Identification of native atrial G-protein-regulated inwardly rectifying K+ (GIRK4) channel homomultimers. J Biol Chem 1998;273:27499–27504.
13.
Dascal N, Schreibmayer W, Lim NF, Wang W, Chavkin C, DiMagno L, et al: Atrial G-protein-activated K+ channel: expression cloning and molecular properties. Proc Natl Acad Sci USA 1993;90:10235–10239.
14.
Krapivinsky G, Gordon EA, Wickman K, Velimirović B, Krapivinsky L, Clapham DE: The G-protein-gated atrial K+ channel IKAch is a heteromultimer of two inwardly rectifying K+-channel proteins. Nature 1995;374:135–141.
15.
Miake J, Marbán E, Nuss HB: Functional role of inward rectifier current in heart probed by Kir2.1 overexpression and dominant-negative suppression. J Clin Invest 2003;111:1529–1536.
16.
Hibino H, Inanobe A, Furutani K, Murakami S, Findlay I, Kurachi Y: Inwardly rectifying potassium channels: their structure, function, and physiological roles. Physiol Rev 2010;90:291–366.
17.
Nattel S: New ideas about atrial fibrillation 50 years on. Nature 2002;415:219–226.
18.
Yang Y, Li J, Lin X, Yang Y, Hong K, Wang L, et al: Novel KCNA5 loss-of-function mutations responsible for atrial fibrillation. J Hum Genet 2009;54:277–283.
19.
Olesen MS, Jespersen T, Nielsen JB, Liang B, Møller DV, Hedley P, et al: Mutations in sodium channel β-subunit SCN3B are associated with early-onset lone atrial fibrillation. Cardiovasc Res 2010 Dec 2, Epub ahead of print.
20.
Watanabe H, Darbar D, Kaiser DW, Jiramongkolchai K, Chopra S, Donahue BS, et al: Mutations in sodium channel β-1- and β-2-subunits associated with atrial fibrillation. Circ Arrhythm Electrophysiol 2009;2:268–275.
21.
Olesen MS, Jabbari J, Holst AG, Nielsen JB, Steinbrüchel DA, Jespersen T, et al: Screening of KCNN3 in patients with early-onset lone atrial fibrillation. EP Europace 2010, in press.
22.
Gudbjartsson DF, Arnar DO, Helgadottir A, Gretarsdottir S, Holm H, Sigurdsson A, et al: Variants conferring risk of atrial fibrillation on chromosome 4q25. Nature 2007;448:353–357.
23.
Benjamin EJ, Rice KM, Arking DE, Pfeufer A, van Noord C, Smith AV, et al: Variants in ZFHX3 are associated with atrial fibrillation in individuals of European ancestry. Nat Genet 2009;41:879–881.
24.
Gudbjartsson DF, Holm H, Gretarsdottir S, Thorleifsson G, Walters GB, Thorgeirsson G, et al: A sequence variant in ZFHX3 on 16q22 associates with atrial fibrillation and ischemic stroke. Nat Genet 2009;41:876–878.
25.
Ellinor PT, Lunetta KL, Glazer NL, Pfeufer A, Alonso A, Chung MK, et al: Common variants in KCNN3 are associated with lone atrial fibrillation. Nat Genet 2010;42:240–244.
26.
Zhang C, Yuan G, Cheng Z, Xu M, Hou L, Wei F: The single nucleotide polymorphisms of Kir3.4 gene and their correlation with lone paroxysmal atrial fibrillation in Chinese Han population. Heart Lung Circ 2009;18:257–261.
27.
Rodriguez S, Gaunt TR, Day INM: Hardy-Weinberg equilibrium testing of biological ascertainment for mendelian randomization studies. Am J Epidemiol 2008;169:505–514.
28.
Hirschhorn JN, Lohmueller K, Byrne E, Hirschhorn K: A comprehensive review of genetic association studies. Genet Med 2002;4:45–61.
29.
Ioannidis JP, Ntzani EE, Trikalinos TA, Contopoulos-Ioannidis DG: Replication validity of genetic association studies. Nat Genet 2001;29:306–309.
30.
Sinner MF, Pfeufer A, Akyol M, Beckmann B, Hinterseer M, Wacker A, et al: The non-synonymous coding IKr-channel variant KCNH2-K897T is associated with atrial fibrillation: results from a systematic candidate gene-based analysis of KCNH2 (HERG). Eur Heart J 2008;29:907–914.
31.
Holm H, Gudbjartsson DF, Arnar DO, Thorleifsson G, Thorgeirsson G, Stefansdottir H, et al: Several common variants modulate heart rate, PR interval and QRS duration. Nat Genet 2010;42:117–122.
32.
Pfeufer A, van Noord C, Marciante KD, Arking DE, Larson MG, Smith AV, et al: Genome-wide association study of PR interval. Nat Genet 2010;42:153–159.
33.
Hunt R, Sauna ZE, Ambudkar SV, Gottesman MM, Kimchi-Sarfaty C: Silent (synonymous) SNPs: should we care about them? Methods Mol Biol 2009;578:23–39.
34.
Chamary JV, Parmley JL, Hurst LD: Hearing silence: non-neutral evolution at synonymous sites in mammals. Nat Rev Genet 2006;7:98–108.
35.
Goymer P: Synonymous mutations break their silence. Nat Rev Genet 2007;8:92.
36.
Purvis IJ, Bettany AJE, Santiago TC, Coggins JR, Duncan K, Eason R, et al: The efficiency of folding of some proteins is increased by controlled rates of translation in vivo: a hypothesis. J Mol Biol 1987;193:413–417.
37.
Ivanov IG, Saraffova AA, Abouhaidar MG: Unusual effect of clusters of rare arginine (AGG) codons on the expression of human interferon alpha 1 gene in Escherichia coli. Int J Biochem Cell Biol 1997;29:659–666.
38.
Parmley JL, Hurst LD: How do synonymous mutations affect fitness? BioEssays. 2007;29:515–519.
© 2011 S. Karger AG, Basel
2011
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.